FDA approves Perrigo's miconazole
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Perrigo's abbreviated new drug application for the private-label version of Monistat-1 Combination Pack. Perrigo's OTC Miconazole Nitrate Vaginal Cream and Suppository will ship immediately, the Allegan, Mich.-based private label firm says June 3. Johnson & Johnson/McNeil's Monistat generates about $90 million in annual sales, Perrigo pointed out. Perrigo also said patent litigation by J&J was dismissed, and the approval includes 180 days of generic marketing exclusivity. Analysts with Collins Stewart say the launch of Perrigo's store-brand Monistat product is positive and "gives us greater confidence in [Perrigo's] manufacturing capabilities.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.